Episurf Medical (Nasdaq: EPIS B) today announces that the abstract “Clinical results after treatment with a patient customised mini metal implant for focal cartilage damage in the knee”, has been accepted for a podium presentation at the Swedish Orthopaedic Society’s annual congress, which will take place in Malmö, Sweden, on August 29 – September 2, 2022. The presentation will be held by Prof. Karl Eriksson from Stockholm South Hospital and The Karolinska Institute, Stockholm, Sweden.

The abstract reports on the clinical outcome for patients having undergone treatment with Episurf Medical’s personalised knee implant Episealer® for treatment of isolated chondral and osteochondral defects in the knee, at Stockholm South Hospital.

“The study performed at Stockholm South Hospital is the first prospective, investigator-initiated study with follow up of Episealer® patients. We highly appreciate this initiative, and we are happy that the Swedish Orthopaedic Society decided to accept this abstract for a podium presentation, which confirms the interest in the clinical results of our technology. We are looking forward to taking part of the results from this ongoing study”, says Pål Ryfors, CEO Episurf Medical.

CisionBlockPro\Cision\FeedItem Object
(
    [HtmlCompanyInformation:protected] => <p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><strong><span style="font-size:10pt">About Episurf Medical</span></strong></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><em>Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</em></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"></p>
    [HtmlContact:protected] => <p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><strong><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;">For more information, please contact:</span></strong></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">P&aring;l Ryfors, CEO, Episurf Medical<br /></span><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;">Tel:</span><span style="font-size: 10pt;">+46 (0) 709 62 36 69<br /></span><span style="font-size: 10pt;">Email:&nbsp;</span><a href="mailto:pal.ryfors@episurf.com">pal.ryfors@episurf.com</a></p>
    [HtmlTitle:protected] => <h1 style="line-height:120%"><span style="font-family:arial,helvetica,sans-serif"><strong>Results from study with Episealer&reg; Knee implant accepted for presentation at Swedish orthopaedic congress</strong></span></h1>
    [HtmlHeader:protected] => 
    [HtmlIntro:protected] => 
    [Body:protected] => Episurf Medical (Nasdaq: EPIS B) today announces that the abstract “Clinical results after treatment with a patient customised mini metal implant for focal cartilage damage in the knee”, has been accepted for a podium presentation at the Swedish Orthopaedic Society's annual congress, which will take place in Malmö, Sweden, on August 29 – September 2, 2022. The presentation will be held by Prof. Karl Eriksson from Stockholm South Hospital and The Karolinska Institute, Stockholm, Sweden.
The abstract reports on the clinical outcome for patients having undergone treatment with Episurf Medical’s personalised knee implant Episealer® for treatment of isolated chondral and osteochondral defects in the knee, at Stockholm South Hospital.
“The study performed at Stockholm South Hospital is the first prospective, investigator-initiated study with follow up of Episealer® patients. We highly appreciate this initiative, and we are happy that the Swedish Orthopaedic Society decided to accept this abstract for a podium presentation, which confirms the interest in the clinical results of our technology. We are looking forward to taking part of the results from this ongoing study”, says Pål Ryfors, CEO Episurf Medical.
    [HtmlBody:protected] => <p style="margin-bottom:11px;margin-top:12px"><span><span style="font-size:11pt"><span><span style="font-family:arial,helvetica,sans-serif"><span style="color:#0e101a">Episurf Medical (Nasdaq: EPIS B) today announces that the abstract “<em>Clinical results after treatment with a patient customised mini metal implant for focal cartilage damage in the knee</em>”, has been accepted for a podium presentation at the Swedish Orthopaedic Society's annual congress, which will take place in Malmö, Sweden, on August 29 – September 2, 2022. The presentation will be held by P</span>rof. Karl Eriksson from Stockholm South Hospital and The Karolinska Institute, Stockholm, Sweden.</span></span></span></span></p>
<p style="margin-bottom:11px"><span><span style="font-size:11pt"><span><span style="font-family:arial,helvetica,sans-serif"><span style="color:#0e101a">The abstract reports on the clinical outcome for patients having undergone treatment with Episurf Medical’s personalised knee implant Episealer® for treatment of isolated chondral and osteochondral defects in the knee, at Stockholm South Hospital.</span></span></span></span></span></p>
<p style="margin-bottom:11px"><span><span style="font-size:11pt"><span><span style="font-family:arial,helvetica,sans-serif"><em><span style="color:#0e101a">“The study performed at Stockholm South Hospital is the first prospective, investigator-initiated study with follow up of Episealer</span></em><strong><span style="color:#0e101a">®</span></strong><em><span style="color:#0e101a"> patients. We highly appreciate this initiative, and we are happy that the Swedish Orthopaedic Society decided to accept this abstract for a podium presentation, which confirms the interest in the clinical results of our technology. We are looking forward to taking part of the results from this ongoing study”,</span></em><span style="color:#0e101a"> says Pål Ryfors, CEO Episurf Medical.</span></span></span></span></span></p>
    [ServiceCategories:protected] => Array
        (
            [0] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => Twitter
                    [Name:protected] => Twitter
                    [Value:protected] => 9341
                )
            [1] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => LinkedIn
                    [Name:protected] => LinkedIn
                    [Value:protected] => 14520
                )
            [2] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => Facebook
                    [Name:protected] => Facebook
                    [Value:protected] => 14326
                )
        )
    [LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
    [CompanyInformation:protected] => About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
    [Contact:protected] => For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
    [Header:protected] => 
    [Keywords:protected] => Array
        (
            [0] => Episurf Medical
            [1] => EpiSurf
            [2] => Pål Ryfors
            [3] => Episealer
        )
    [QuickFacts:protected] => Array
        (
        )
    [Categories:protected] => Array
        (
        )
    [Videos:protected] => Array
        (
        )
    [Files:protected] => Array
        (
            [0] => CisionBlockPro\Cision\File Object
                (
                    [IsMain:protected] => 1
                    [MediaType:protected] => File
                    [Url:protected] => https://mb.cision.com/Main/14691/3614311/1614854.pdf
                    [FileName:protected] => wkr0006.pdf
                    [Title:protected] => Results from study with Episealer® Knee implant accepted for presentation at Swedish orthopaedic congress
                    [Description:protected] => Results from study with Episealer® Knee implant accepted for presentation at Swedish orthopaedic congress
                    [CreateDate:protected] => 2022-08-15T15:00:16.727Z
                    [Keywords:protected] => Array
                        (
                        )
                    [Extension:protected] => pdf
                )
        )
    [Quotes:protected] => Array
        (
        )
    [ExternalLinks:protected] => Array
        (
        )
    [EmbeddedItems:protected] => Array
        (
        )
    [Id:protected] => 4329117
    [EncryptedId:protected] => 69EEB35BEFCD9D2D
    [IsRegulatory:protected] => 
    [PublishDate:protected] => 2022-08-15T15:00:00Z
    [LastChangeDate:protected] => 2022-08-15T15:00:16.71Z
    [Title:protected] => Results from study with Episealer® Knee implant accepted for presentation at Swedish orthopaedic congress
    [Intro:protected] => 
    [IptcCode:protected] => 04016003
    [InformationType:protected] => PRM
    [LanguageCode:protected] => en
    [CountryCode:protected] => se
    [CanonicalUrl:protected] => 
    [CisionWireUrl:protected] => https://news.cision.com/episurf/r/results-from-study-with-episealer--knee-implant-accepted-for-presentation-at-swedish-orthopaedic-con,c3614311
    [LanguageVersions:protected] => Array
        (
            [0] => CisionBlockPro\Cision\LanguageVersion Object
                (
                    [Code:protected] => sv
                    [ReleaseId:protected] => 4329115
                )
        )
    [Images:protected] => Array
        (
        )
    [Tickers:protected] => Array
        (
            [0] => stdClass Object
                (
                    [Symbol] => EPIS B
                    [ISIN] => SE0003491562
                    [PrimaryListing] => 1
                    [IsShare] => 1
                    [MarketPlaceSymbol] => STO
                    [MarketPlaceName] => Stockholmsbörsen
                    [MarketPlaceBloombergCode] => SS
                    [MarketPlaceMarketWireCode] => OMX
                    [MarketPlaceIsRegulated] => 1
                    [MarketPlaceCountryCode] => SE
                )
        )
)